Top

Published in:

01-12-2020 | Plasmodium Falciparum | Commentary

Commentary in reply to a publication on Plasmodium falciparum pre-erythrocytic stage vaccine development

Authors: François P. Roman, Margherita Coccia, Lode Schuerman

Published in: Malaria Journal | Issue 1/2020

Abstract

We have read the publication of Molina-Franky and colleagues on Plasmodium falciparum pre-erythrocytic stage vaccine development (Malaria Journal, 2020;19:56). The commentary revises some of their statements on the RTS,S/AS01 vaccine that are considered either imprecise or incorrect.

Molina-Franky J, Cuy-Chaparro L, Camargo A, Reyes C, Gómez M, Salamanca DR, et al. Plasmodium falciparum pre-erythrocytic stage vaccine development. Malar J. 2020;19:56.CrossRef

Agnandji ST, Fernandes JF, Bache EB, Ramharter M. Clinical development of RTS, S/AS malaria vaccine: a systematic review of clinical Phase I-III trials. Future Microbiol. 2015;10:1553–78.CrossRef

European Medicine Agency Mosquirix H-W-2300. https://www.ema.europa.eu/en/mosquirix-h-w-2300. Accessed 27 Feb 2020.

Malaria vaccine: WHO position paper. Wkly Epidemiol Rec. 2016;91:33–52.

WHO. Q&A on the Malaria Vaccine Implementation Pilot (MVIP): https://www.who.int/malaria/media/malaria-vaccine-implementation-qa/en/. Accessed 27 Feb 2020.

Ballou WR. Malaria vaccines in development. Expert Opin Emerg Drugs. 2005;10:489–503.CrossRef

Vekemans J, Leach A, Cohen J. Development of the RTS, S/AS malaria candidate vaccine. Vaccine. 2009;27(Suppl 6):G67.CrossRef

Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Human Vaccin. 2010;6:90–6.CrossRef

Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, et al. Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine. N Engl J Med. 2015;373:2025–37.CrossRef

10.

Leach A, Vekemans J, Lievens M, Ofori-Anyinam O, Cahill C, Owusu-Agyei S, et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS, S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J. 2011;10:224.CrossRef

11.

The RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863–75.CrossRef

12.

The RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284–95.CrossRef

13.

The RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685.CrossRef

14.

The RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45.CrossRef

15.

Chaudhury S, Ockenhouse CF, Regules JA, Dutta S, Wallqvist A, Jongert E, et al. Malar J. 2016;15:301.CrossRef

16.

Kurup SP, Butler NS, Harty JT. T cell-mediated immunity to malaria. Nat Rev Immunol. 2019;19:457–71.CrossRef

17.

Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193:1920–30.CrossRef

18.

Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines. 2017;2:25.CrossRef

19.

Detienne S, Welsby I, Collignon C, Wouters S, Coccia M, Delhaye S, et al. Central role of CD169⁺ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01. Sci Rep. 2016;6:39475.CrossRef

20.

Welsby I, Detienne S, N’Kuli F, Thomas S, Wouters S, Bechtold V, et al. Lysosome-dependent activation of human dendritic cells by the vaccine adjuvant QS-21. Front Immunol. 2017;7:663.CrossRef

Title: Commentary in reply to a publication on Plasmodium falciparum pre-erythrocytic stage vaccine development
Authors: François P. Roman
Margherita Coccia
Lode Schuerman
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Plasmodium Falciparum
Malaria
Published in: Malaria Journal / Issue 1/2020
Electronic ISSN: 1475-2875
DOI: https://doi.org/10.1186/s12936-020-03334-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Commentary in reply to a publication on Plasmodium falciparum pre-erythrocytic stage vaccine development

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Patterns of pesticide usage in agriculture in rural Tanzania call for integrating agricultural and public health practices in managing insecticide-resistance in malaria vectors

Are we interconnected? A qualitative study on the role and perception of different actors on malaria social behaviour change interventions in rural Mozambique

Lessons learned, challenges and outlooks for decision-making after a decade of experience monitoring the impact of indoor residual spraying in Benin, West Africa

Malaria serology data from the Guiana shield: first insight in IgG antibody responses to Plasmodium falciparum, Plasmodium vivax and Plasmodium malariae antigens in Suriname

Binding of human serum proteins to Plasmodium falciparum-infected erythrocytes and its association with malaria clinical presentation

An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria infection model

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page